Minghui Pharmaceutical (Hangzhou) Ltd
16
11
14
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 16 trials
100.0%
+13.5% vs industry average
25%
4 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (16)
A Study of MHB009C in Patients With Advanced Solid Tumors
Role: lead
A Study of MHB042C in Patients With Advanced Solid Tumors
Role: lead
A Study of MHB048C in Patients With Advanced Solid Tumors
Role: lead
MHB018A Treatment in Patients With Active Thyroid Eye Disease
Role: lead
Open-Label Extension Study of MHB018A in Subjects With Thyroid Eye Disease
Role: lead
MHB018A Treatment in Patients With Chronic Thyroid Eye Disease
Role: lead
A Study of MHB039A for Advanced Solid Tumor
Role: lead
A Study of MHB036C for Advanced Solid Tumor
Role: lead
A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors
Role: lead
A Study of MHB088C Combined With MHB039A in Patients With Advanced Malignant Solid Tumors
Role: lead
A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer
Role: lead
A Phase 3 Study of MH004 Ointment in Patients With Mild to Moderate Atopic Dermatitis
Role: lead
MH004 Ointment in Healthy Adult Volunteers and Participants With Mild to Moderate Atopic Dermatitis
Role: lead
Phase II Clinical Trial of MH004 Ointment in Patients With Non-segmental Vitiligo
Role: lead
A Study of MHB046C Injection in Patients With Advanced Solid Tumors
Role: lead
A Study of MHB118C Injection in Patients With Advanced Solid Tumors
Role: lead
All 16 trials loaded